Steven C Campbell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6754780/publications.pdf

Version: 2024-02-01

223 papers

15,154 citations

23565 58 h-index 119 g-index

243 all docs

243 docs citations

times ranked

243

8929 citing authors

#	Article	IF	CITATIONS
1	Every decade counts: a narrative review of functional recovery after partial nephrectomy. BJU International, 2023, 131, 165-172.	2.5	25
2	Evaluation of Urinalysis-Based Screening for Urothelial Carcinoma in Patients With Lynch Syndrome. Diseases of the Colon and Rectum, 2022, 65, 40-45.	1.3	5
3	Parenchymal Volume Replacement by Renal Cell Carcinoma Prior to Intervention: Predictive Factors and Functional Implications. Urology, 2022, 159, 139-145.	1.0	3
4	Predicting GFR after radical nephrectomy: the importance of split renal function. World Journal of Urology, 2022, 40, 1011-1018.	2.2	16
5	Offâ€elamp partial nephrectomy: Level 1 data regarding realâ€world utility (or futility). BJU International, 2022, 129, 131-132.	2.5	1
6	What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy?. European Urology, 2022, 81, 492-500.	1.9	19
7	Split Renal Function Is Fundamentally Important for Predicting Functional Recovery After Radical Nephrectomy. European Urology Open Science, 2022, 40, 112-116.	0.4	10
8	Partial Versus Radical Nephrectomy: Complexity of Decision-Making and Utility of AUA Guidelines. Clinical Genitourinary Cancer, 2022, 20, 501-509.	1.9	5
9	Optimizing prediction of new-baseline glomerular filtration rate after radical nephrectomy: are algorithms really necessary?. International Urology and Nephrology, 2022, 54, 2537-2545.	1.4	4
10	The effect of partial nephrectomy on blood pressure in patients with solitary kidney. World Journal of Urology, 2021, 39, 1577-1582.	2.2	4
11	PTEN Hamartoma Tumor Syndrome: A Case of Renal Cell Carcinoma in a Young Female. Urology, 2021, 148, 113-117.	1.0	3
12	Infiltrative Renal Masses: Clinical Significance and Fidelity of Documentation. European Urology Oncology, 2021, 4, 264-273.	5.4	15
13	Partial nephrectomy for patients with limited life expectancy?. Nature Reviews Urology, 2021, 18, 193-194.	3.8	0
14	Editorial Comment. Journal of Urology, 2021, 205, 684-685.	0.4	0
15	Infiltrative Renal Malignancies: Imaging Features, Prognostic Implications, and Mimics. Radiographics, 2021, 41, 487-508.	3.3	12
16	New Baseline Renal Function after Radical or Partial Nephrectomy: A Simple and Accurate Predictive Model. Journal of Urology, 2021, 205, 1310-1320.	0.4	31
17	Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. Current Oncology, 2021, 28, 1921-1926.	2.2	6
18	Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma?. European Urology, 2021, 79, 774-780.	1,9	20

#	Article	IF	Citations
19	Infiltrative tumor interface with normal renal parenchyma in locally advanced renal cell carcinoma: Clinical relevance and pathological implications. International Journal of Urology, 2021, 28, 1233-1239.	1.0	7
20	Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. Journal of Urology, 2021, 206, 199-208.	0.4	242
21	Editorial Comment. Journal of Urology, 2021, 206, 1019-1019.	0.4	O
22	Quantitative Assessment of a Case Based Digital Learning Curriculum for Testicular Cancer. Urology, 2020, 135, 28-31.	1.0	2
23	Re: Impact of Acute Kidney Injury and its Duration on Long-term Renal Function after Partial Nephrectomy. European Urology, 2020, 77, 282.	1.9	0
24	Re: Prediction of Significant Estimated Glomerular Filtration Rate Decline After Renal Unit Removal to Aid in the Clinical Choice Between Radical and Partial Nephrectomy in Patients with a Renal Mass and Normal Renal Function. European Urology, 2020, 78, 765.	1.9	0
25	Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome. Npj Genomic Medicine, 2020, 5, 40.	3.8	9
26	EDITORIAL COMMENT. Urology, 2020, 137, 37.	1.0	0
27	Unplanned Conversion from Minimally Invasive to Open Kidney Surgery: The Impact of Robotics. Journal of Endourology, 2020, 34, 955-963.	2.1	8
28	Split renal function in patients with renal masses: utility of parenchymal volume analysis vs nuclear renal scans. BJU International, 2020, 125, 686-694.	2.5	22
29	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. Clinical Genitourinary Cancer, 2020, 18, 500-508.	1.9	10
30	Commentary RE: Increased Incidence of Serendipitously Discovered Renal Cell Carcinoma. Urology, 2020, 145, 333.	1.0	1
31	Long-Term Oncologic Outcomes After Laparoscopic and Robotic Tumor Enucleation for Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 595457.	2.8	5
32	Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. Journal of Urology, 2020, 203, 475-485.	0.4	25
33	Compensatory Changes in Parenchymal Mass and Function after Radical Nephrectomy. Journal of Urology, 2020, 204, 42-49.	0.4	20
34	Infiltrative Renal Masses: Clinical Challenges. Urology, 2020, 145, 3-8.	1.0	2
35	Open partial nephrectomy when a non-flank approach is required: indications and outcomes. World Journal of Urology, 2019, 37, 515-522.	2.2	3
36	Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. Investigational New Drugs, 2019, 37, 1231-1238.	2.6	22

#	Article	IF	CITATIONS
37	EDITORIAL COMMENT. Urology, 2019, 128, 29.	1.0	O
38	Functional Recovery From Prolonged Warm Ischemia: Compelling Case Scenarios. Urology, 2019, 132, 22-27.	1.0	2
39	The Complete Spectrum of Infiltrative Renal Masses: Clinical Characteristics and Prognostic Implications. Urology, 2019, 130, 86-92.	1.0	13
40	Vascularized Parenchymal Mass Preserved with Partial Nephrectomy: Functional Impact and Predictive Factors. European Urology Oncology, 2019, 2, 97-103.	5.4	21
41	Re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. European Urology, 2019, 75, 198.	1.9	2
42	Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes. European Urology, 2019, 75, 477-491.	1.9	65
43	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. Clinical Genitourinary Cancer, 2019, 17, e505-e512.	1.9	24
44	Can We Predict Functional Outcomes after Partial Nephrectomy?. Journal of Urology, 2019, 201, 693-701.	0.4	18
45	Renal Cancer Surgery in Patients without Preexisting Chronic Kidney Diseaseâ€"ls There a Survival Benefit for Partial Nephrectomy?. Journal of Urology, 2019, 201, 1088-1096.	0.4	8
46	The Impact of Renal Tumor Surgery on Kidney Function. , 2019, , 221-246.		0
47	Editorial Comment. Journal of Urology, 2019, 202, 74-75.	0.4	0
48	Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer. Clinical Advances in Hematology and Oncology, 2019, 17, 697-707.	0.3	5
49	Kidney, Ureteral, and Bladder Cancer. Medical Clinics of North America, 2018, 102, 231-249.	2.5	11
50	Editorial Comment. Journal of Urology, 2018, 199, 654-654.	0.4	0
51	Impact of Comorbidities on Functional Recovery from Partial Nephrectomy. Journal of Urology, 2018, 199, 1433-1439.	0.4	33
52	Imprudent Utilization of Partial Nephrectomy. Urology, 2018, 117, 22-26.	1.0	4
53	Tumor Contact Surface Area As a Predictor of Functional Outcomes After Standard Partial Nephrectomy: Utility and Limitations. Urology, 2018, 116, 106-113.	1.0	9
54	Ischemia and Functional Recovery from Partial Nephrectomy: Refined Perspectives. European Urology Focus, 2018, 4, 572-578.	3.1	41

#	Article	IF	CITATIONS
55	Atypical Epithelioid Angiomyolipoma: A Rare Variant With Malignant Potential. Urology, 2018, 112, 20-22.	1.0	2
56	Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis. Clinical Genitourinary Cancer, 2018, 16, e289-e295.	1.9	10
57	Predictors of Long-Term Survival after Renal Cancer Surgery. Journal of Urology, 2018, 199, 384-392.	0.4	14
58	Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery. BJU International, 2018, 121, 93-100.	2.5	42
59	Use of 99m Tc-sestamibi Single-photon Emission Computed Tomography / X-ray Computed Tomography in the Diagnosis of Hybrid Oncocytic / Chromophobe Tumor in a Pediatric Patient. Urology, 2018, 113, 206-208.	1.0	5
60	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 31-37.	1.6	49
61	EDITORIAL COMMENT. Urology, 2018, 122, 42.	1.0	0
62	EDITORIAL COMMENT. Urology, 2018, 122, 49-50.	1.0	0
63	Active Surveillance for Localized Small Renal Masses: Current Perspectives. European Urology Oncology, 2018, 1, 188-189.	5.4	3
64	A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43.	0.4	0
65	2017 AUA Renal Mass and Localized Renal Cancer Guidelines: Imaging Implications. Radiographics, 2018, 38, 2021-2033.	3.3	63
66	Acute Kidney Injury after Partial Nephrectomy of Solitary Kidneys: Impact on Long-Term Stability of Renal Function. Journal of Urology, 2018, 200, 1295-1301.	0.4	41
67	Devascularized Parenchymal Mass Associated with Partial Nephrectomy: Predictive Factors and Impact on Functional Recovery. Journal of Urology, 2017, 198, 787-794.	0.4	25
68	End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 529.e1-529.e7.	1.6	7
69	Renal Ischemia and Functional Outcomes Following Partial Nephrectomy. Urologic Clinics of North America, 2017, 44, 243-255.	1.8	34
70	Excised Parenchymal Mass During Partial Nephrectomy: Functional Implications. Urology, 2017, 103, 129-135.	1.0	23
71	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. European Urology, 2017, 72, 64-75.	1.9	91
72	Functional Comparison of Renal Tumor Enucleation Versus Standard Partial Nephrectomy. European Urology Focus, 2017, 3, 437-443.	3.1	30

#	Article	IF	Citations
73	MP59-15 LONG-TERM OUTCOMES AFTER RENAL CANCER SURGERY: PREDICTORS OF CHRONIC KIDNEY DISEASE AND NON-RENAL CANCER MORTALITY. Journal of Urology, 2017, 197, .	0.4	3
74	Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. European Urology, 2017, 71, 495.	1.9	0
75	Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Modern Pathology, 2017, 30, 146-156.	5.5	66
76	Functional Implications of Renal Tumor Enucleation Relative to Standard Partial Nephrectomy. Urology, 2017, 99, 162-168.	1.0	28
77	Proteinuria in Patients Undergoing Renal Cancer Surgery: Impact on Overall Survival and Stability of Renal Function. European Urology Focus, 2016, 2, 616-622.	3.1	15
78	End-stage Renal Disease after Renal Surgery: Partial Nephrectomy is Protective, but to What Degree and Consequence?. European Urology, 2016, 70, 562-563.	1.9	3
79	MP41-10 RENAL TUMOR ENUCLEATION MAXIMALLY PRESERVES RENAL PARENCHYMAL VOLUME COMPARED TO STANDARD PARTIAL NEPHRECTOMY. Journal of Urology, 2016, 195, .	0.4	1
80	Preoperative Prediction and Postoperative Surgeon Assessment of Volume Preservation Associated With Partial Nephrectomy: Comparison With Measured Volume Preservation. Urology, 2016, 93, 124-129.	1.0	11
81	Editorial Comment. Journal of Urology, 2016, 196, 999-999.	0.4	O
82	Re: The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. European Urology, 2016, 70, 699.	1.9	0
83	Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma. BJU International, 2016, 118, 927-934.	2.5	7
84	Acute Ipsilateral Renal Dysfunction after Partial Nephrectomy in Patients with a Contralateral Kidney: Spectrum Score to Unmask Ischemic Injury. European Urology, 2016, 70, 692-698.	1.9	20
85	Author Reply. Urology, 2016, 87, 113.	1.0	O
86	Acute Kidney Injury after Partial Nephrectomy: Role of Parenchymal Mass Reduction and Ischemia and Impact on Subsequent Functional Recovery. European Urology, 2016, 69, 745-752.	1.9	99
87	Functional Recovery From Extended Warm Ischemia Associated With Partial Nephrectomy. Urology, 2016, 87, 106-113.	1.0	22
88	Re: Raj Satkunasivam, Sheaumei Tsai, Sumeet Syan, et al. Robotic Unclamped "Minimal-margin―Partial Nephrectomy: Ongoing Refinement of the Anatomic Zero-ischemia Concept. Eur Urol 2015;68:705–12. European Urology, 2016, 69, e95-e96.	1.9	1
89	Surgical Salvage of Thermal Ablation Failures for Renal Cell Carcinoma. Journal of Urology, 2016, 195, 594-600.	0.4	21
90	Editorial Comment. Urology, 2015, 86, 1-2.	1.0	0

#	Article	IF	CITATIONS
91	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. Journal of Urology, 2015, 194, 297-303.	0.4	80
92	Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. JAMA Oncology, 2015, 1, 212.	7.1	9
93	Editorial Comment. Urology, 2015, 85, 735-736.	1.0	1
94	Re: Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. European Urology, 2015, 68, 539.	1.9	0
95	Decline in Renal Function after Partial Nephrectomy: Etiology and Prevention. Journal of Urology, 2015, 193, 1889-1898.	0.4	240
96	Tumor Enucleation for Sporadic Localized Kidney Cancer: Pro and Con. Journal of Urology, 2015, 194, 623-625.	0.4	37
97	Analysis of Atrophy After Clamped Partial Nephrectomy and Potential Impact of Ischemia. Urology, 2015, 85, 1417-1423.	1.0	16
98	Reply. Urology, 2015, 85, 1423.	1.0	0
99	Comparison of 2 Computed Tomography–based Methods to Estimate Preoperative and Postoperative Renal Parenchymal Volume and Correlation With Functional Changes After Partial Nephrectomy. Urology, 2015, 86, 80-86.	1.0	11
100	Survival and Functional Stability in Chronic Kidney Disease Due to Surgical Removal of Nephrons: Importance of the New Baseline Glomerular Filtration Rate. European Urology, 2015, 68, 996-1003.	1.9	170
101	Evaluation of an Electronic Platform for Problem Based Learning for Subspecialty Fellows. Urology Practice, 2015, 2, 133-137.	0.5	1
102	Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 112.e15-112.e21.	1.6	60
103	Editorial Comment. Urology, 2015, 86, 305-306.	1.0	O
104	Multicenter Validation of Surgeon Assessment of Renal Preservation in Comparison to Measurement With 3D Image Analysis. Urology, 2015, 86, 534-538.	1.0	17
105	Editorial Comment. Urology, 2014, 84, 1412-1413.	1.0	0
106	Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. International Journal of Urology, 2014, 21, 880-885.	1.0	49
107	Is all chronic kidney disease created equal?. Current Opinion in Urology, 2014, 24, 127-134.	1.8	35
108	Tuberous Sclerosis–associated Renal Cell Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1457-1467.	3.7	211

#	Article	IF	CITATIONS
109	Chronic Kidney Disease Due to Surgical Removal of Nephrons: Relative Rates of Progression and Survival. Journal of Urology, 2014, 192, 1057-1063.	0.4	119
110	Compensatory Hypertrophy after Partial and Radical Nephrectomy in Adults. Journal of Urology, 2014, 192, 1612-1619.	0.4	66
111	Assessment of Outcomes in Partial Nephrectomy Incorporating Detailed Functional Analysis. Urology, 2014, 84, 1128-1133.	1.0	6
112	Editorial Comment. Urology, 2014, 84, 867-868.	1.0	1
113	Editorial Comment. Urology, 2014, 83, 724-725.	1.0	0
114	Predictors of Precision of Excision and Reconstruction in Partial Nephrectomy. Journal of Urology, 2014, 192, 30-35.	0.4	43
115	Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes. European Urology, 2014, 65, 193-200.	1.9	103
116	Poorly Functioning Kidneys Recover from Ischemia after Partial Nephrectomy as Well as Strongly Functioning Kidneys. Journal of Urology, 2014, 192, 665-670.	0.4	44
117	Editorial Comment. Urology, 2014, 84, 334.	1.0	0
118	Editorial Comment. Urology, 2014, 84, 332-333.	1.0	0
119	Kidney Cancer., 2014,, 309-323.		1
120	The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study. World Journal of Urology, 2013, 31, 1159-1164.	2.2	23
121	Association Between Warm Ischemia Time and Renal Parenchymal Atrophy After Partial Nephrectomy. Journal of Urology, 2013, 189, 1638-1642.	0.4	72
122	Surgically Induced Chronic Kidney Disease May be Associated with a Lower Risk of Progression and Mortality than Medical Chronic Kidney Disease. Journal of Urology, 2013, 189, 1649-1655.	0.4	221
123	Development of a Clinical Prediction Model for Assessment of Malignancy Risk in Bosniak III Renal Lesions. Urology, 2013, 82, 630-635.	1.0	26
124	Consolidative surgery after targeted therapy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 914-919.	1.6	3
125	Analytical and biological validation of a multiplex immunoassay for acute kidney injury biomarkers. Clinica Chimica Acta, 2013, 415, 88-93.	1.1	22
126	Single Institutional Cost Analysis of 325 Robotic, Laparoscopic, and Open Partial Nephrectomies. Urology, 2013, 81, 533-539.	1.0	53

#	Article	IF	Citations
127	10-Year Oncologic Outcomes After Laparoscopic and Open Partial Nephrectomy. Journal of Urology, 2013, 190, 44-49.	0.4	155
128	Re: Precise Segmental Renal Artery Clamping Under the Guidance of Dual-source Computed Tomography Angiography During Laparoscopic Partial Nephrectomy. European Urology, 2013, 63, 964-965.	1.9	2
129	Evaluation of a Case-based Urology Learning Program. Urology, 2013, 82, 1207-1210.	1.0	11
130	Parenchymal Volume Preservation and Ischemia During Partial Nephrectomy: Functional and Volumetric Analysis. Urology, 2013, 82, 263-269.	1.0	238
131	Fenoldopam and Renal Function After Partial Nephrectomy in a Solitary Kidney: A Randomized, Blinded Trial. Urology, 2013, 81, 340-346.	1.0	16
132	The Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney. Journal of Urology, 2013, 189, 1198-1202.	0.4	54
133	Editorial Comment. Urology, 2013, 81, 275-276.	1.0	2
134	Comparative Outcomes of Laparoscopic and Open Adrenalectomy for Adrenocortical Carcinoma: Single, High-Volume Center Experience. Annals of Surgical Oncology, 2013, 20, 1456-1461.	1.5	82
135	Re: A Prospective, Randomized EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 2012, 62, 564-565.	1.9	3
136	A Nonischemic Approach to Partial Nephrectomy is Optimal. Journal of Urology, 2012, 187, 387-390.	0.4	38
137	Functional Recovery After Partial Nephrectomy: Effects of Volume Loss and Ischemic Injury. Journal of Urology, 2012, 187, 1667-1673.	0.4	204
138	Nephrometry Score is Associated with Volume Loss and Functional Recovery After Partial Nephrectomy. Journal of Urology, 2012, 188, 39-44.	0.4	69
139	Renal Function After Partial Nephrectomy: Effect of Warm Ischemia Relative to Quantity and Quality of Preserved Kidney. Urology, 2012, 79, 356-360.	1.0	327
140	Editorial Comment. Urology, 2012, 79, 377-378.	1.0	0
141	Editorial Comment. Urology, 2012, 79, 825-826.	1.0	2
142	Diameter-Axial-Polar Nephrometry: Integration and Optimization of R.E.N.A.L. and Centrality Index Scoring Systems. Journal of Urology, 2012, 188, 384-390.	0.4	81
143	Malignant Renal Tumors. , 2012, , 1413-1474.e33.		48
144	A nonischemic approach to partial nephrectomy is optimal. No. Journal of Urology, 2012, 187, 388-90.	0.4	8

#	Article	IF	Citations
145	Limited Warm Ischemia During Elective Partial Nephrectomy has Only a Marginal Impact on Renal Functional Outcomes. Journal of Urology, 2011, 185, 1598-1603.	0.4	77
146	Comparison of Cold and Warm Ischemia During Partial Nephrectomy in 660 Solitary Kidneys Reveals Predominant Role of Nonmodifiable Factors in Determining Ultimate Renal Function. Journal of Urology, 2011, 185, 421-427.	0.4	314
147	Laparoscopic Cryoablation for a 3 cm Nonhilar Renal Tumor. Journal of Urology, 2011, 185, 14-16.	0.4	2
148	Small Renal Masses: Risk Prediction and Contemporary Management. Hematology/Oncology Clinics of North America, 2011, 25, 717-736.	2.2	10
149	Acute Kidney Injury: Novel Biomarkers and Potential Utility for Patient Care in Urology. Urology, 2011, 77, 5-11.	1.0	29
150	Neoadjuvant Systemic Therapy or Early Cystectomy? Single-center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Carcinoma of the Bladder. Urology, 2011, 77, 867-870.	1.0	70
151	Partial Nephrectomy Does Not Compromise Survival in Patients With Pathologic Upstaging to pT2/pT3 or High-grade Renal Tumors Compared With Radical Nephrectomy. Urology, 2011, 77, 1142-1146.	1.0	57
152	Editorial Comment. Urology, 2011, 77, 786.	1.0	0
153	Inadequacy of Biopsy for Diagnosis of Upper Tract Urothelial Carcinoma: Implications for Conservative Management. Urology, 2011, 78, 82-86.	1.0	169
154	Bilateral Synchronous Sporadic Renal Tumors: Pathologic Concordance and Clinical Implications. Urology, 2011, 78, 1095-1099.	1.0	28
155	Effect of Parenchymal Volume Preservation on Kidney Function After Partial Nephrectomy. Journal of Urology, 2011, 186, 405-410.	0.4	164
156	Renal mass sampling: An enlightened perspective. International Journal of Urology, 2011, 18, 5-19.	1.0	47
157	The Epidemiology of Renal Cell Carcinoma. European Urology, 2011, 60, 615-621.	1.9	817
158	Small renal masses: Toward more rational treatment. Cleveland Clinic Journal of Medicine, 2011, 78, 539-547.	1.3	24
159	Is radical nephrectomy overused in elderly kidney cancer patients?. Aging Health, 2010, 6, 587-589.	0.3	3
160	Partial Nephrectomy Is Associated with Improved Overall Survival Compared to Radical Nephrectomy in Patients with Unanticipated Benign Renal Tumours. European Urology, 2010, 58, 293-298.	1.9	172
161	Every Minute Counts When the Renal Hilum Is Clamped During Partial Nephrectomy. European Urology, 2010, 58, 340-345.	1.9	604
162	Comparison of Warm Ischemia Versus No Ischemia During Partial Nephrectomy on a Solitary Kidney. European Urology, 2010, 58, 331-336.	1.9	139

#	Article	IF	Citations
163	Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer, 2010, 116, 2967-2973.	4.1	178
164	Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer, 2010, 116, 3119-3126.	4.1	227
165	Association of percentage of tumour burden removed with debulking nephrectomy and progressionâ€free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factorâ€ŧargeted therapy. BJU International, 2010, 106, 1266-1269.	2.5	65
166	Performance of the Chronic Kidney Disease-Epidemiology Study Equations for Estimating Glomerular Filtration Rate Before and After Nephrectomy. Journal of Urology, 2010, 183, 896-902.	0.4	59
167	Aggregate Lymph Node Metastasis Diameter and Survival After Radical Cystectomy for Invasive Bladder Cancer. Urology, 2010, 75, 382-386.	1.0	32
168	The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis. Urology, 2010, 75, 1138-1143.	1.0	28
169	Elective Partial Nephrectomy in Patients With Clinical T1b Renal Tumors Is Associated With Improved Overall Survival. Urology, 2010, 76, 631-637.	1.0	133
170	Urologic Emergencies in Pregnancy. Urology, 2010, 76, 453-460.	1.0	28
171	Laparoendoscopic Single-site Radical Cystectomy and Pelvic Lymph Node Dissection: Initial Experience and 2-Year Follow-up. Urology, 2010, 76, 857-861.	1.0	50
172	Nephrectomy Induced Chronic Renal Insufficiency is Associated With Increased Risk of Cardiovascular Death and Death From Any Cause in Patients With Localized cT1b Renal Masses. Journal of Urology, 2010, 183, 1317-1323.	0.4	394
173	Renal Functional Outcomes After Partial Nephrectomy With Extended Ischemic Intervals are Better Than After Radical Nephrectomy. Journal of Urology, 2010, 184, 1286-1290.	0.4	91
174	Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of Renal Tubular Origin. Archives of Pathology and Laboratory Medicine, 2010, 134, e25-e30.	2.5	37
175	Laparoscopic Radical Cystectomy: Current Status, Outcomes, and Patient Selection. Current Treatment Options in Oncology, 2009, 10, 243-255.	3.0	24
176	Integration of surgery and systemic therapy in the management of metastatic renal cancer. Current Urology Reports, 2009, 10, 35-41.	2.2	9
177	Editorial Comment. Journal of Urology, 2009, 182, 2599-2600.	0.4	3
178	Gonadal Vein Tumor Thrombus in Metastatic Renal Cell Carcinoma. Urology, 2009, 73, 1229-1230.	1.0	4
179	Guideline for Management of the Clinical T1 Renal Mass. Journal of Urology, 2009, 182, 1271-1279.	0.4	1,697
180	Renal Function Assessment in the Era of Chronic Kidney Disease: Renewed Emphasis on Renal Function Centered Patient Care. Journal of Urology, 2009, 182, 435-444.	0.4	76

#	Article	IF	CITATIONS
181	Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy. Journal of Urology, 2009, 182, 2257-2264.	0.4	55
182	Renal cell carcinoma. Lancet, The, 2009, 373, 1119-1132.	13.7	1,363
183	Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma. Journal of Urology, 2009, 181, 518-523.	0.4	153
184	Surgical Resection of Renal Cell Carcinoma After Targeted Therapy. Journal of Urology, 2009, 182, 881-886.	0.4	122
185	Histopathologic Features and Clinical Outcomes in 71 Cases of Bladder Diverticula. Archives of Pathology and Laboratory Medicine, 2009, 133, 791-796.	2.5	62
186	Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. BJU International, 2008, 101, 969-972.	2.5	28
187	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney: Clinical, Radiographic, and Pathologic Characteristics. Urology, 2008, 71, 1142-1148.	1.0	82
188	Current status of prostate-sparing cystectomy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 486-493.	1.6	19
189	Surgical Salvage of Renal Cell Carcinoma Recurrence After Thermal Ablative Therapy. Journal of Urology, 2008, 180, 104-109.	0.4	88
190	Renal Mass Biopsy—A Renaissance?. Journal of Urology, 2008, 179, 20-27.	0.4	344
191	Choice of Operation for Clinically Localized Renal Tumor. Urologic Clinics of North America, 2008, 35, 645-655.	1.8	30
192	Salvage of local recurrence after primary thermal ablation for small renal masses. Expert Review of Anticancer Therapy, 2008, 8, 1899-1905.	2.4	13
193	The paradigm shift in renal mass biopsy. Clinical Advances in Hematology and Oncology, 2008, 6, 253-4, 258.	0.3	2
194	Prostate-sparing cystectomy: has Pandora's box been opened?. Expert Review of Anticancer Therapy, 2007, 7, 1003-1014.	2.4	12
195	Perioperative Outcomes with Laparoscopic Radical Cystectomy: "Pure Laparoscopic―and "Open-Assisted Laparoscopic―Approaches. Urology, 2007, 70, 910-915.	1.0	113
196	The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy. Journal of Urology, 2007, 177, 1978-1984.	0.4	81
197	A Preoperative Prognostic Nomogram for Solid Enhancing Renal Tumors 7 cm or Less Amenable to Partial Nephrectomy. Journal of Urology, 2007, 178, 429-434.	0.4	226
198	Laparoscopic radical cystectomy. BJU International, 2007, 100, 455-476.	2.5	9

#	Article	IF	CITATIONS
199	1096: Predicting Occult Malignancy in the Prostate Prior to Radical Cystectomy. Journal of Urology, 2007, 177, 362-362.	0.4	1
200	Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU International, 2006, 98, 1172-1175.	2.5	30
201	Staging of Renal Cell Carcinoma: Past, Present, and Future. Clinical Genitourinary Cancer, 2006, 5, 190-197.	1.9	19
202	Mixed Epithelial and Stromal Tumor of the Kidney and Cystic Nephroma Share Overlapping Features: Reappraisal of 15 Lesions. Archives of Pathology and Laboratory Medicine, 2006, 130, 80-85.	2.5	72
203	Society of Urologic Oncology position statement: Redefining the management of hormoneâ€refractory prostate carcinoma. Cancer, 2005, 103, 11-21.	4.1	33
204	Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology, 2005, 66, 1251-1255.	1.0	40
205	Renal Neoplasms in Younger Adults: Analysis of 112 Tumors From a Single Institution According to the New 2004 World Health Organization Classification and 2002 American Joint Committee on Cancer Staging System. Archives of Pathology and Laboratory Medicine, 2005, 129, 487-491.	2.5	37
206	$\hat{l}\pm 1$ -antitrypsin inhibits angiogenesis and tumor growth. International Journal of Cancer, 2004, 112, 1042-1048.	5.1	46
207	Renal Tumor With Overlapping Distal Nephron Morphology and Karyotype. Archives of Pathology and Laboratory Medicine, 2004, 128, 1274-1278.	2.5	12
208	Peroxisome Proliferator-Activated Receptor \hat{I}^3 Ligands Improve the Antitumor Efficacy of Thrombospondin Peptide ABT510. Molecular Cancer Research, 2004, 2, 541-550.	3.4	55
209	Nephrectomy in metastatic renal cell carcinoma. Current Treatment Options in Oncology, 2003, 4, 363-372.	3.0	58
210	Metastatic renal cell carcinoma. Current Treatment Options in Oncology, 2003, 4, 385-390.	3.0	248
211	Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. Urology, 2002, 60, 218-222.	1.0	20
212	Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. International Journal of Cancer, 2002, 98, 682-689.	5.1	134
213	Juxtaglomerular apparatus tumor: a rare, surgically correctable cause of hypertension. Reviews in Urology, 2002, 4, 192-5.	0.9	11
214	Hand-Assisted vs. Retroperitoneal Laparoscopic Nephrectomy. Journal of Endourology, 2001, 15, 899-902.	2.1	22
215	Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate, 2001, 49, 293-305.	2.3	126
216	Solitary Fibrous Tumor of the Prostate. Archives of Pathology and Laboratory Medicine, 2001, 125, 274-277.	2.5	22

#	Article	IF	CITATIONS
217	Contemporary management of renal cell carcinoma with coexistent renal artery disease: update of the cleveland clinic experience. Urology, 2000, 56, 382-386.	1.0	20
218	BOOK REVIEWSM. Maizels, D. Rosenbaum and B. Keating,: Getting to Dry: How to Help Your Child Overcome Bedwetting Journal of Urology, 2000, 163, 1064-1064.	0.4	0
219	Patterns of Tumor Recurrence and Guidelines for Followup After Nephron Sparing Surgery for Sporadic Renal Cell Carcinoma. Journal of Urology, 1997, 157, 2067-2070.	0.4	237
220	Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology, 1995, 46, 352-355.	1.0	91
221	Complications of Nephron Sparing Surgery for Renal Tumors. Journal of Urology, 1994, 151, 1177-1180.	0.4	253
222	Management of Renal Cell Carcinoma with Coexistent Renal Artery Disease. Journal of Urology, 1993, 150, 808-813.	0.4	18
223	Delayed Allograft Autotransplantation after Excision of a Large Symptomatic Renal Artery Pseudoaneurysm. Journal of Urology, 1993, 149, 361-363.	0.4	15